ArticleJournal of nanobiotechnology2026
Hydrogel delivery platform of engineered apoptotic vesicles for ischemic stroke therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke, induced by the occlusion of cerebral blood vessels, represents a leading cause of global morbidity and mortality. Although thrombolytic therapy and mechanical thrombectomy are cornerstone treatments for restoring cerebral perfusion, their clinical effectiveness is severely constrained by a narrow therapeutic window. This study presents a reactive oxygen species (ROS) - responsive hydrogel platform loaded with engineered apoptotic vesicles (apoVs) designed to simultaneously target multiple post-stroke pathological processes. Proteomic analyses reveal that apoV isolated from apoptotic neural stem cells are enriched in proteins associated with angiogenesis and neuroprotection. In vitro investigations and in vivo animal experiment further demonstrate that the hydrogel can alleviate oxidative stress, promote angiogenesis and protect nerve injury by releasing hydrogen sulfide (H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.